Header

UZH-Logo

Maintenance Infos

Prognostic relevance of LDH and serum S-100 levels in Stage IV melanoma with known BRAF mutation status


Frauchiger, A L; Mangana, J; Rechsteiner, M; Moch, H; Seifert, Burkhardt; Braun, R; Dummer, R; Goldinger, S M (2016). Prognostic relevance of LDH and serum S-100 levels in Stage IV melanoma with known BRAF mutation status. British Journal of Dermatology, 174(4):823-830.

Abstract

BACKGROUND Activating mutations of the BRAF-gene provide an important treatment target in melanoma patients. However, prognostic role of several biochemical markers in relation to the mutation status is not clear yet. OBJECTIVES Prognostic significance of BRAF mutation in melanoma patients was analyzed and correlated to different additional markers. PATIENTS AND METHODS 162 melanoma stage IV patients with known BRAF-mutation status were included. Clinical, histopathological and laboratory information was collected and compared between BRAF-mutant (BRAFm) and wildtype (BRAFwt) melanoma patients at time of first distant metastasis. RESULTS 88 patients (54.3%) were BRAFm (V600E or K). At first distant metastasis S100B levels in BRAFm patients were more frequently elevated and significantly higher (p = 0.013 resp. p = 0.021). Median overall survival (mOS) was significantly longer in BRAFwt patients with normal compared to patients with elevated S100B levels (p < 0.001). However, in BRAFm melanoma, elevated S100B levels showed no prognostic influence (p = 0.18). Elevated LDH levels had a significant negative impact on mOS in both BRAFm and BRAFwt groups. mOS was increased for BRAFm patients treated with a BRAF inhibitor (BRAFi) compared to BRAFm patients without BRAFi treatment (p = 0.012). However, no difference in mOS between BRAFm patients without BRAFi treatment and BRAFwt patients was observed. CONCLUSIONS The analysis confirms the better mOS in BRAFm patients treated with BRAFi. Interestingly, BRAFm patients not treated with BRAFi show similar survival curves as BRAFwt patients. Additionally, elevated LDH is a BRAF-independent prognostic parameter in all patients, whereas S100B has prognostic significance in BRAFwt patients only. This article is protected by copyright. All rights reserved.

Abstract

BACKGROUND Activating mutations of the BRAF-gene provide an important treatment target in melanoma patients. However, prognostic role of several biochemical markers in relation to the mutation status is not clear yet. OBJECTIVES Prognostic significance of BRAF mutation in melanoma patients was analyzed and correlated to different additional markers. PATIENTS AND METHODS 162 melanoma stage IV patients with known BRAF-mutation status were included. Clinical, histopathological and laboratory information was collected and compared between BRAF-mutant (BRAFm) and wildtype (BRAFwt) melanoma patients at time of first distant metastasis. RESULTS 88 patients (54.3%) were BRAFm (V600E or K). At first distant metastasis S100B levels in BRAFm patients were more frequently elevated and significantly higher (p = 0.013 resp. p = 0.021). Median overall survival (mOS) was significantly longer in BRAFwt patients with normal compared to patients with elevated S100B levels (p < 0.001). However, in BRAFm melanoma, elevated S100B levels showed no prognostic influence (p = 0.18). Elevated LDH levels had a significant negative impact on mOS in both BRAFm and BRAFwt groups. mOS was increased for BRAFm patients treated with a BRAF inhibitor (BRAFi) compared to BRAFm patients without BRAFi treatment (p = 0.012). However, no difference in mOS between BRAFm patients without BRAFi treatment and BRAFwt patients was observed. CONCLUSIONS The analysis confirms the better mOS in BRAFm patients treated with BRAFi. Interestingly, BRAFm patients not treated with BRAFi show similar survival curves as BRAFwt patients. Additionally, elevated LDH is a BRAF-independent prognostic parameter in all patients, whereas S100B has prognostic significance in BRAFwt patients only. This article is protected by copyright. All rights reserved.

Statistics

Citations

4 citations in Web of Science®
3 citations in Scopus®
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Institute of Pathology and Molecular Pathology
04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2016
Deposited On:22 Dec 2015 07:57
Last Modified:28 Apr 2016 01:01
Publisher:Wiley-Blackwell Publishing, Inc.
ISSN:0007-0963
Publisher DOI:https://doi.org/10.1111/bjd.14347
PubMed ID:26659191

Download

Full text not available from this repository.
View at publisher

TrendTerms

TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents.
You can navigate and zoom the map. Mouse-hovering a term displays its timeline, clicking it yields the associated documents.

Author Collaborations